ABBOTT TO SELL SMITHKLINE BEECHAM HOSPITAL ANTIBIOTICS LINE
Executive Summary
ABBOTT TO SELL SMITHKLINE BEECHAM HOSPITAL ANTIBIOTICS LINE beginning in January under a marketing and distribution agreement announced Dec. 21. In the U.S., Abbott will exclusively market the injectable vial formulations of Ancef (cefazolin sodium), Tazicef (ceftazidime), Bactocill (oxacillin), Nallpen (nafcillin), Ticar (ticarcillin disodium) and Totacillin (ampicillin). SmithKline Beecham will continue to manufacture the products, which are all off-patent. Abbott said it does not plan any labeling or packaging changes for the drugs.